BRIM Business Summary

BRIM Biotechnology (6885.TW) is a clinical-stage biopharmaceutical company that operates on a translational science business model, utilizing a virtual R&D approach to develop first-in-class regenerative therapies. The company generates revenue primarily through strategic out-licensing agreements, milestone payments, and collaborative development fees, notably partnering with Grand Pharmaceutical for Greater China rights. Its primary business segments are focused on ophthalmology—headlined by its lead asset BRM421 for Dry Eye Disease (DED) and BRM424 for neurotrophic keratitis—and orthopedics, specifically BRM521 for osteoarthritis. These candidates are built upon BRIM’s proprietary Pigment Epithelium-Derived Factor-derived Short Peptide (PDSP) technology platform, which stimulates stem cell-mediated tissue repair. Within the competitive landscape, BRIM contends with global giants such as AbbVie (Restasis), Novartis (Xiidra), and Bausch + Lomb (Miebo); however, it distinguishes itself as a niche innovator by targeting corneal nerve and tissue regeneration rather than the anti-inflammatory or palliative mechanisms employed by established market leaders. The company was founded in 2013 by Dr. Haishan Jang and Dr. Frank Lee, both seasoned veterans of the international pharmaceutical industry. The current leadership team is headed by Chairman Andrew Lin (Qun Lin), a prominent financier and former Chairman of Lotus Pharmaceutical with a background at McKinsey & Company, and CEO Dr. Wen-Chyi Shyu, who previously held senior roles at Takeda and has overseen over 15 market approvals. Following the retirement of co-founder Frank Lee in early 2026, Lin Zheng-wen serves as the Chief Technology Officer, overseeing the technical advancement of the PDSP platform. BRIM is supported by a high-profile board and investor base, including independent director Dr. Johnsee Lee (former President of ITRI) and institutional backing from Fubon Financial Holding Venture Capital and Affinity Capital Fund One.